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Introduction
This report aims to define guidelines for the indication of hematopoietic stem cell 
transplantation in the treatment of acute myeloid leukemia in Brazil. This report on the role 
of hematopoietic stem cell transplantation in the treatment of acute myeloid leukemia was 
presented to and ratified by the Brazilian Bone Marrow Transplantation Society at the meeting 
on the Brazilian Guidelines for hematopoietic stem cell transplantation. This consensus is based 
on a review of the international literature and on the Brazilian experience in hematopoietic 
stem cell transplantation. The optimal treatment for acute myeloid leukemia in first complete 
remission is not yet defined. There is a consensus on the indication of allogeneic transplantation 
with myeloablative conditioning for patients presenting cytogenetic changes considered high 
risk. Allogeneic transplantation is not indicated in first complete remission for patients with low 
cytogenetic risk, and it appears that allogeneic transplantation, autologous transplantation, and 
consolidation chemotherapy are equivalent for patients with intermediate risk. In advanced disease 
and secondary leukemia, allogeneic transplant is the main therapeutic tool. New medications and 
therapeutic regimens have enabled the adoption of transplant in older individuals.
Prevalence and mortality rates of acute myeloid leukemia
Acute myeloid leukemia (AML) accounts for 90% of all cases of acute leukemia in adults, 
with an average age at diagnosis of 63 years(1). In the United States, 18,000 new cases of leukemia 
are diagnosed each year; 12,000 of which are acute(2,3). In the state of Rio Grande do Sul, Brazil, a 
hundred new cases of relapsed AML are diagnosed annually in patients of all ages, with an incidence 
of 0.5-1:100,000 people and an average age at diagnosis of 42 years. Seventy-nine per cent of cases 
of relapsed AML occur in adults (> 18 years). After five years, only 90 patients (17%) of the 532 
patients diagnosed between 1996 and 2000 were still alive(4). These data are in accordance with 
the data in the literature, and suggest that outside clinical trials, and despite the advancement of 
knowledge in this field, AML is still a fatal disease in the vast majority of the cases. Estimates of the 
Brazilian Instituto Nacional do Câncer (Inca) indicate that the number of new cases of leukemia in 
Brazil in 2012 will be 4570 in males and 3940 in females, with a risk of five new cases per 100,000 
men and four per 100,000 women(5). But in Brazil, just as there is a lack of specific data on each 
type of leukemia worldwide(3), the database of the National Health Service, DATASUS, only gathers 
information on the incidence and mortality for ‘leukemia’ in general, and does not specifically 
differentiate acute myeloid leukemia. For leukemia in general, the mortality rate in 2010 ranged from 
1.20 (Amapá) to 4.08 (Rio Grande do Sul) per 100,000 female patients with leukemia and from 0.81 
(Acre) to 5.28 (Rio Grande do Sul) per 100,000 male patients(6). Meanwhile, DATASUS recorded 
5935 deaths from leukemia in Brazil in 2010(7). It is likely that the Brazilian data are underestimated.
 
Hematopoietic stem cell transplantation and acute myeloid leukemia
AML is currently the most common indication for hematopoietic stem cell transplantation 
(HSCT) worldwide(8). The rationale for the indication of HSCT is based on the fact that this 
disease is the result of the accumulation of cells produced by extremely rare malignant stem cells, 
which are capable of self-renewing(9) and resistant to the cytotoxic effects of chemotherapy(10), 
resulting in disease relapse. Due to the resistance to chemotherapy, the malignant stem cell can 
undergo additional mutations(11) and is destroyed in a small number of patients, even in those 
who undergo doses of myeloablative chemotherapy or radiation administered for HSCT. The 
benefits of allogeneic HSCT derive from the destruction of these stem cells by the donor’s 
immune system [T and natural killer (NK) lymphocytes], the graft-versus-leukemia effect(12,13).
Issues related to the disease and the patient greatly influence the endpoints of HSCT 
for AML. It has recently been systematically shown that the presence of comorbidities 
greatly compromises the results of HSCT, as a result of which this therapeutic option is not 
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recommended for patients with high comorbidity burdens(14). 
Therefore, for the elderly, as described below, in patients with 
low comorbidity burdens or no comorbidities at all, the results of 
HSCT may be similar to those observed in young patients who 
receive this therapeutic option. 
Results of hematopoietic stem cell transplantation for 
acute myeloid leukemia - international report
Allogeneic HSCT, a treatment for AML but which is 
accompanied by considerable morbimortality, is available to few 
patients due to age, lack of donors or unavailable hospital beds. 
Data from the Center of International Blood and Marrow Transplant 
Research (CIBMTR) show that until 2009, around 20,234 cases 
of AML were transplanted according to all hospitals that reported 
this data. Of these, around 52% underwent allogeneic HSCT from 
related donors and 48% from unrelated donors(15). According to 
Appelbaun(16), of the 13,000 new cases of AML annually reported 
in the United States, considering transplant hospitals that are not 
members of the CIBMTR, no more than 2000 patients have the 
chance of undergoing HSCT. However, the availability for unrelated 
donors has increased with the use of allogeneic transplantation, 
especially in patients between the ages of 40 to 65 years. In the 
literature, half of the donors for transplantation in first complete 
remission (CR1) are unrelated and in later stages of the disease, 
unrelated donors are more frequently used(3).
The results of related allogeneic HSCT with a myeloablative 
regimen for AML depend, above all, on the stage of the disease, early 
(CR1), intermediate (≥ second CR) or advanced (relapsed or refractory), 
with survival rates of around 53%, 44% and 20% in 5 years, respectively; 
while for myeloablative HSCT from unrelated donors, survival is around 
40% in the early and intermediate stages, and 18% in the advanced stage, 
over the same period of time(15). The data on HSCT for AML reported 
by Brazilian hospitals to the CIBMTR are, overall, very similar to those 
published. However, it is important to point out that not all cases of AML 
in CR1 are indicated for HSCT (see below). 
Risk factors 
In addition to risk factors related to the stage of the disease 
and the presence of comorbidities, the classification of risk 
according to cytogenetic changes as proposed by the South West 
Oncology Group (SWOG)(17) and the Medical Research Council 
(MRC) AML 10 Trial(18) (Table 1) is essential to define treatment 
for the different sub-types of AML. A series of molecular changes 
has been associated with AML and trials have been carried out to 
better define their prognostic role (Table 2)(12,19-22).
 
Indication of allogeneic hematopoietic stem cell 
transplantation for acute myeloid leukemia in first 
complete remission 
A recently published meta-analysis, which included 6700 
patients enrolled in prospective trials on HSCT for AML in CR1, 
showed that the results for related allogeneic HSCT with high 
doses of chemotherapy are higher than for autologous HSCT in 
high- and intermediate-risk patients. Allogeneic HSCT is not 
indicated for low risk patients(23). Low-risk patients (Table 1), 
with core binding factor (CBF) leukemia, CBF-AML [(8;21), 
inv(16) or t(16;16)] or acute progranulocytic leukemia [t(15-17)] 
have a moderate risk of relapse and around 50% of survival in 5 
years when they undergo only chemotherapy(24).
Indications of autologous hematopoietic stem cell 
transplantation for acute myeloid leukemia in first 
complete remission
Although successive meta-analyses have demonstrated 
the non-superiority of autologous HSCT over high dose 
chemotherapy(25-27), experience in Brazil in the treatment of AML 
seems to suggest a role for autologous HSCT (28). Between 1996 and 
2000, the five-year survival rate for the 532 patients with AML was 
17%(4). However, it is important to point out that in this study, the 
Table 1 - Criteria for risk classification in acute myeloid leukemia
South West Oncology Group(17) Criteria Medical Research Council
(18) Criteria 
identical to  South West Oncology Group except
Favorable
t(15;17) + any other abnormality
inv(16)/t(16;16)/del(16q) + any other abnormality
t(8;21) without del(9q) or complex karyotype t(8;21) + any other abnormality
Intermediate 
+8, -Y, +6, del(12p) abnormal 11q23
normal karyotype del(9q), del(7q) – without other abnormalities
complex karyotype (≥ 3 abnormalities but < 5 
abnormalities)
all significant abnormalities
unknown prognosis
Unfavorable 
-5/del(5q), -7/del(7q)
t(8;21) with del(9q)
inv(3q), abnormal 11q23, 20q.
21q, del(9q), t(6;9)
T(9:22), abnormal 17p
complex karyotypes (≥ 3 abnormalities) complex karyotypes (≥ 5 abnormalities)
Unknown All other clonal anomalies with < 3 abnormalities
58
Silla LM, Dulley F, Saboya R, Paton E, Kerbauy F, Arantes AM, Hamerschlak N
Rev Bras Hematol Hemoter. 2013;35(1):56-61
Table 2 - Acute myeloid leukemia molecular abnormalities(12)
Gene Clinical and biological characteristics
Nucleophosmin 1
(NPM1)
Protein with pleomorphic functions associated with the female gender, number of blasts (CD33+ and 34- or 
below) and high HDL, 25% to 35% of AML predominantly with NK (45-62%) associated with FLT3-ITD and 
mutation of the TKD genotype NPM1mut/FLT3-ITDneg associated with good prognosis and appears to not 
benefit from myeloablative allogeneic HSCT. Where present, it is indicative of good prognosis, regardless of the 
FLT3-ITD status(19)
FLT3 From the family of tyrosine-kinase receptors class III, it is associated with poor prognostic FLT3-ITDpos ITDpos; FLT3-TKDpos and has an uncertain prognosis
ITD 28% to 34% of NK-AML is associated with unfavorable prognosis; the determination of ITD seems important
TKD Mutation of around 11% to 14% of the NK-AML associated with improved OS; high levels of this molecule are associated with improved OS
CCAAT enhancer 
binding protein alpha 
(CEBPA)
Important transcription factor in the differentiation of neutrophils particularly associated with NK-AML and 
del(9q) associated with higher CR rate, improved RFS and OS
myeloid/lymphoid 
gene (MLL)
It is partial tandem duplication; 5% to 11% of NK-AML associated with shorter duration of CR or with reduced 
RFS or EFS; autologous HSCT appears to have a favorable role in the endpoints
RAS NRAS mutation found in ~ 9% of the NK-AML without prognostic significance
Wilms' tumor 
suppressor gene 
(WT1)
Mutation found in ~ 10% of the NK-AML, this mutation does not appear to have an impact on the endpoints, but 
is associated with the WT1mut/FLT3-ITDpos genotype - increases the risk of failure during induction(20)
DNMT3A Mutation recently described in ~ 20% of NK-AMLIndependently associated with poor prognosis(21)
ITD: internal tandem duplication; TKD: mutation in the tyrosine-kinase domain; NK: normal karyotype; CR: complete remission; OS: overall survival; 
RFS: relapse-free survival; EFS: event-free survival
surviving patients and those in CR after 5 years included, though 
few in number, patients who had undergone allogeneic HSCT and 
patients in palliative care or untreated. However, in a retrospective 
study on the results of allogeneic and autologous HSCT for AML 
in Brazil(29), there were no differences for overall survival (OS) 
between these two types of transplantations. Therefore, in Brazil, 
autologous HSCT is an accepted procedure of consolidation therapy 
for AML, after two rounds of induction and at least one round of 
consolidation therapy, for intermediate-risk patients without any 
HLA-compatible donor. In low-risk patients [without the c-KIT 
mutation and in the presence of Nucleophosmin 1 (NPM1)], 
chemotherapy is only recommended at high doses and allogeneic 
or autologous HSCT is not indicated. In cases of unfavorable 
cytogenetics, allogeneic HSCT is preferable and should be 
indicated whenever possible. For AML-M3 in molecular second 
complete remission (CR2), autologous HSCT is acceptable(30).
 
Consolidation therapy and hematopoietic stem cell 
transplantation
The number of consolidation therapies prior to an allogeneic 
HSCT has never been investigated prospectively. A CIBMTR 
retrospective study involving 431 patients suggests that additional 
chemotherapy after CR is not beneficial and allogeneic HSCT 
should be performed as soon as possible(31). For autologous HSCT, 
as mentioned above, in Brazil, at least one round of consolidation 
therapy is recommended prior to transplantation(28). 
 
Bone marrow or peripheral blood transplant
In a meta-analysis of nine randomized studies that included 
1111 patients, it was demonstrated that peripheral blood (PB) 
HSCT is superior to bone marrow (BM) HSCT as it results in a 
reduced relapse rate, improved OS and improved disease-free 
survival (DFS)(32). However, it is important to highlight that 
PB HSCT is associated with a significant risk of extensive 
graft-versus-host disease (GVHD), particularly in unrelated HSCT(33) 
and should be reserved for patients with advanced disease (≥ CR2)(34). 
Therapeutic regimens
The comparison between busulfan (Bu) + cyclophosphamide 
(CY) and Bu + total body irradiation (TBI) administered to 581 
patients (381 administered with Bu-CY and 200 with Bu-TBI) 
showed that, although Bu-TBI seems to be related to reduced relapse, 
significant differences were not observed for transplanted-related 
mortality (TRM), DFS and OS(35). More recently, the fludarabine 
(Flu) + Bu association has been used and seems to be associated 
with less toxicity and efficacy similar to Bu-CY in a retrospective 
comparison(36). Although promising and similar results to this 
therapeutic regimen were observed in Brazil by Conexão Caipira 
collaborative group(37), it is important to emphasize that the original 
protocol was designed for the use of intravenous Bu (Flu 30 mg/m2, 
Bu 1 mg/kg x 16 doses orally, target Bu). Based on this evidence, 
it is acceptable in Brazil(28) to use three therapeutic options, 
Bu-CY/Bu-melphalan (Mel), Flu-Bu and Bu-TBI, depending on 
the treatment center’s experience in each option and availability. 
 
Unrelated allogeneic hematopoietic stem cell 
transplantation
With the exception of one trial that involved a small 
number of patients(38), there have been no prospective studies 
comparing unrelated and related allogeneic HSCT. The results of 
retrospective analysis suggest that unrelated allogeneic HSCT is 
an option for patients who do not have HLA-compatible related 
59
Bone marrow transplantation and acute myeloid leukemia: Brazilian guidelines
Rev Bras Hematol Hemoter. 2013;35(1):56-61
donors. With more sensitive molecular techniques for HLA 
typing, the results for unrelated HSCT seem to be similar to those 
of related HSCT in high-risk AML patients(39).
In a retrospective study reported by the CIBMTR involving 
2223 patients who underwent related and unrelated HSCT, 
although a higher incidence of acute Grade II-IV GVHD was 
observed in the unrelated transplanted patients, transplant-related 
mortality (TRM) and OS were similar between the two identical 
HLA groups (8:8)(40). As for the origin of the cells, the results 
seem to be similar between unrelated BM and umbilical cord 
blood donors(41).
 
Hematopoietic stem cell transplantation in relapsed 
or refractory acute myeloid leukemia
Allogeneic HSCT is accepted in the treatment of refractory 
AML(42). In one publication, the three-year survival rate for 1673 
transplanted patients with relapsed or refractory AML was 19%(43). 
Nevertheless, in the late relapsed sub-group, without blasts in the 
peripheral blood, with performance status > 90%, and favorable 
cytogenetics and who received grafts from related HLA-compatible 
donors, the three-year survival rate was 43%. Approximately 30% 
of patients who were prematurely transplanted during relapse (i.e., 
< 30% of blasts in the BM) had disease-free survival similar to 
patients transplanted in CR2(44). Although the difference between 
relapsed or refractory AML is not clear in the literature, HSCT can 
be an option for this group of patients.
 
Hematopoietic stem cell transplantation in the elderly
The median age of patients with AML/myelodysplastic 
syndrome (MDS) is 65 years(45). The number of patients with 
long-term survival is very low, regardless of the choice of 
chemotherapeutic regimen used for remission induction or 
consolidation(46,47). Historically, myeloablative transplant in the 
elderly has been performed little and this is associated with an 
extremely high mortality rate associated with the therapeutic 
regimen(48). It has become clear that age per se is not an obstacle for 
HSCT(49), since comorbidities and performance status exceed age in 
the determination of the risk of transplant-related mortality. A two-
year survival of 68% was observed in a study by MD Anderson 
involving patients treated at the Hospital Israelita Albert Einstein 
(HIAE) in Brazil(50). Based on the comparative study between 
intravenous Bu and Flu, and Bu and Cy, which demonstrated 
improved OS, leukemia-free survival and reduced toxicity in 
patients with AML in the Bu-Flu group, 79 patients aged between 
60 and 80 years with AML and MDS were investigated. These data 
confirm that provided that patients have a good performance status, 
the use of therapy with Bu-Flu - using Bu intravenously - can be 
beneficial. HSCT with reduced therapy or reduced toxicity is today a 
well-established treatment for elderly patients with AML(51).
 
Final recommendations
To improve the results and corroborate with the various types 
of HSCT for the treatment of AML in Brazil, a national effort 
should be made for quality karyotyping, and for the development 
of molecular techniques to be used as tools in the classification of 
risk and to categorize the ideal treatment for AML. 
To summarize, the consensus and the respective quality 
determinations of evidence and strength of recommendation were:
- Allogeneic HSCT is recommended for high-risk AML 
(A1).
- Allogeneic HSCT is recommended for intermediate-risk 
AML (B2).
- Allogeneic HSCT is recommended for relapsed/refractory 
AML (C2).
- Autologous HSCT is recommended for AML after 
consolidation therapy (B2).
- Autologous HSCT is recommended for AML in CR1; this 
is preferable to chemotherapy in the Brazilian experience 
(C2).
- Autologous HSCT is accepted for AML-M3 in molecular 
CR2 (C2).
- PB stem cells are a more common source than BM in 
advanced disease (B1).
- The recommended therapeutic regimens include: 
Bu-Cy/Bu-Mel, Flu-Bu and TBI-Cy, TBI-Cy. For umbilical 
cord cases, antithymocyte globulin (ATG) regimens should 
be considered (B1).
- Allogeneic HSCT for the treatment of AML can be 
used in patients aged between 60 and 80 years with 
good performance status and absence of significant 
comorbidities. 
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